Pharmacoeconomic Analysis of 3 Treatment Strategies for Cytomegalovirus Retinitis in Patients with AIDS
- 1 January 1998
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 13 (4) , 461-474
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Preference Values for Visual States in Patients Planning to Undergo Cataract SurgeryMedical Decision Making, 1997
- Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDSAnnals of Internal Medicine, 1997
- German Health Economic Cost Evaluation on Oral Ganciclovir in Treating Cytomegalovirus RetinitisPharmacoEconomics, 1996
- Medicare program; revisions to payment policies and adjustments to the relative value units under the physician fee schedule for calendar year 1996--HCFA. Final rule with comment period.1995
- Oral Ganciclovir as Maintenance Treatment for Cytomegalovirus Retinitis in Patients with AIDSNew England Journal of Medicine, 1995
- Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.1995
- Treatment of Cytomegalovirus Retinitis With an Intraocular Sustained-Release Ganciclovir ImplantArchives of Ophthalmology (1950), 1994
- Ocular Manifestations of Acquired Immune Deficiency SyndromeOphthalmology, 1989
- Cytomegalovirus Infection in Patients with AIDSThe Journal of Infectious Diseases, 1988
- Treatment of Cytomegalovirus Retinitis with GanciclovirOphthalmology, 1987